Literature DB >> 18954746

Highly aggressive lymphomas in adults.

John W Sweetenham1.   

Abstract

Highly aggressive lymphomas are relatively uncommon in adults, comprising approximately 4% to 5% of all non-Hodgkin lymphomas in the United States and Western Europe. The designation of "highly aggressive" is generally restricted to precursor T-cell and B-cell lymphoblastic lymphoma/leukemia and Burkitt's lymphoma/leukemia. Treatment strategies for lymphoblastic lymphoma and Burkitt's lymphoma include complex, highly intensive combination chemotherapy regimens, which may be curative. As with other subtypes of NHL, emerging data from gene-expression profiling and related techniques are helping to define these entities more precisely and identify potential new rational therapeutic targets.

Entities:  

Mesh:

Year:  2008        PMID: 18954746     DOI: 10.1016/j.hoc.2008.07.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy.

Authors:  Stacey M Parker; Horatiu Olteanu; Peter VanTuinen; Colleen A Lawton; Christopher J Schultz; Kathleen K Christians; Timothy S Fenske
Journal:  Int J Hematol       Date:  2009-11-25       Impact factor: 2.490

2.  Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.

Authors:  Matjaz Sever; Jeffrey L Jorgensen; Inga Gurevich; Mariana Pinheiro; Srdan Verstovsek
Journal:  Leuk Res       Date:  2009-05-30       Impact factor: 3.156

3.  Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.

Authors:  Corrado Tarella; Angela Gueli; Federica Delaini; Andrea Rossi; Anna Maria Barbui; Giuseppe Gritti; Cristina Boschini; Daniele Caracciolo; Riccardo Bruna; Marco Ruella; Daniela Gottardi; Roberto Passera; Alessandro Rambaldi
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.